Full-Time

Manager of Accounting AND Sec Reporting

Posted on 4/30/2024

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops off-the-shelf genetically modified T cells

Biotechnology

Senior

San Carlos, CA, USA

Requirements
  • Bachelor’s degree in accounting or finance, CPA preferred
  • Minimum of 7 years of experience including a mix of public accounting and public biotech/pharma industry experience
  • In-depth knowledge of US GAAP, SEC reporting and SOX 404 compliance
  • Hands on experience with Active Disclosure preferred
  • Previous experience with payroll processing
  • High degree of accuracy and attention to detail
  • Organized and able to manage multiple projects while exemplifying stellar interpersonal skills
  • Excellent communication skills (written and oral)
  • Proficient with Microsoft Office (Outlook, Word, Excel, Powerpoint)
  • Experience with Dynamics Business Central
  • Results and goal-oriented mindset with an opportunistic eye towards process improvements
  • Strong ability to prioritize and organize work. Have the agility to adjust quickly to new priorities
  • Must be able to collaborate and communicate effectively
Responsibilities
  • Assist in the preparation of SEC filings and supporting documents
  • Assist in the preparation of quarterly consolidated financials
  • Participate in monthly close process and ensure all responsible GL transactions are accounted for
  • Prepare and book journal entries for month-end close
  • Interact with Accounting team members to ensure timely and accurate analysis and reconciliation of assigned general ledger accounts
  • Collaborate with third-party consulting firm to prepare the Company's stock-based compensation expense
  • Back up payroll including prepare and processing payroll
  • Assist with other payroll tasks as needed
  • Maintain and update SOX documentation and audit schedules for quarterly reviews and annual audits
  • Special projects as requested

Adicet Bio, Inc is at the forefront of developing off-the-shelf genetically modified gamma delta T cells that specifically target tumors. By employing cutting-edge techniques like chimeric antigen receptors and T cell receptor-like antibodies, this biotechnology company is leading the way in enhancing selective tumor targeting and improving treatment persistence for long-lasting effects in patients. Working here offers an opportunity to be part of a pioneering team dedicated to groundbreaking biological research in cancer treatment, positively impacting patient outcomes in a supportive and innovative environment.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-5%

1 year growth

6%

2 year growth

64%